Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 16 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 7674778

    Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine

    Alnylam Pharmaceuticals, Inc. · Granted Mar 9, 2010 · Expires Mar 4, 2030

    granted

  2. US 7674779

    RNAi modulation of MLL-AF4 and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 9, 2010 · Expires Mar 4, 2030

    granted

  3. US 7632932

    Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

    Alnylam Pharmaceuticals, Inc. · Granted Dec 15, 2009 · Expires Dec 10, 2029

    granted

  4. US 7626014

    Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2009 · Expires Nov 26, 2029

    granted

  5. US 7615618

    Oligonucleotides comprising a non-phosphate backbone linkage

    Alnylam Pharmaceuticals, Inc. · Granted Nov 10, 2009 · Expires Nov 5, 2029

    granted

  6. US 7605251

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 20, 2009 · Expires Oct 15, 2029

    granted

  7. US 7592322

    RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 22, 2009 · Expires Sep 17, 2029

    granted

  8. US 7582744

    Chemically modified oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Sep 1, 2009 · Expires Aug 27, 2029

    granted

  9. US 7582745

    Compositions and methods for inhibiting expression of Nav1.8 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 1, 2009 · Expires Aug 27, 2029

    granted

  10. US 7579451

    Oligonucleotides comprising a modified or non-natural nucleobase

    Alnylam Pharmaceuticals, Inc. · Granted Aug 25, 2009 · Expires Aug 20, 2029

    granted

  11. US 7528118

    RNAi modulation of ApoB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  12. US 7517865

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 14, 2009 · Expires Apr 9, 2029

    granted

  13. US 7507809

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 24, 2009 · Expires Mar 19, 2029

    granted

  14. US 7423142

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Pharmaceuticals, Inc. · Granted Sep 9, 2008 · Expires Sep 4, 2028

    granted

  15. US 7361752

    RNAi modulation of MLL-AF4 and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 22, 2008 · Expires Apr 17, 2028

    granted

  16. US 7320965

    Compositions and methods for inhibiting expression of Huntingtin gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 22, 2008 · Expires Jan 17, 2028

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.